8-K: Merck Reports Strong 2025 Growth, Strategic Pipeline Expansion

Merck announced robust fourth-quarter and full-year 2025 financial results, driven by oncology and new product launches, while outlining a strategic 2026 outlook impacted by a major acquisition charge.

Summary

• Fourth-quarter 2025 worldwide sales increased 5% (4% excluding foreign exchange impact) to $16.4 billion.
• Full-year 2025 worldwide sales grew 1% (2% excluding foreign exchange impact) to $65.0 billion.
• Full-year 2025 Non-GAAP EPS rose 17% to $8.98, including $0.20 per share in business development charges.
• KEYTRUDA/KEYTRUDA QLEX sales reached $31.7 billion for the full year, a 7% increase.
• New products WINREVAIR and CAPVAXIVE contributed $1.4 billion and $759 million in full-year sales, respectively.
• Animal Health sales grew 8% (9% excluding foreign exchange impact) to $6.4 billion for the full year.
• GARDASIL/GARDASIL 9 sales declined 39% to $5.2 billion for the full year, primarily due to lower demand in China and Japan.
• Completed the acquisition of Cidara Therapeutics in 2026 for approximately $9.2 billion, adding MK-1406 to the portfolio.
• Announced positive late-stage trial results from 18 Phase 3 trials in 2025 and initiated 21 new Phase 3 studies.
• Provided 2026 financial outlook, anticipating worldwide sales between $65.5 billion and $67.0 billion and Non-GAAP EPS between $5.00 and $5.15, which includes a one-time charge of approximately $3.65 per share for the Cidara acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid performance with strong underlying business momentum and pipeline advancements, despite the significant one-time charge from the Cidara acquisition impacting the 2026 EPS outlook.

Positives

• Strong growth in key oncology product KEYTRUDA/KEYTRUDA QLEX, with full-year sales of $31.7 billion (7% growth).
• Significant contributions from new launches: WINREVAIR ($1.4 billion full-year sales) and CAPVAXIVE ($759 million full-year sales).
• Robust performance in Animal Health, with full-year sales of $6.4 billion (8% growth).
• Positive late-stage trial results from 18 Phase 3 trials in 2025, demonstrating pipeline strength.
• Strategic acquisitions of Verona Pharma (adding OHTUVAYRE) and Cidara Therapeutics (adding MK-1406) are augmenting the portfolio.
• FDA approvals for KEYTRUDA/KEYTRUDA QLEX in combination with Padcev for muscle-invasive bladder cancer (MIBC).
• FDA priority review vouchers received for sac-TMT and enlicitide decanoate, potentially expediting review timelines.
• Agreement with the U.S. government to expand access to medicines and lower costs, including a three-year delay on Section 232 tariffs and a commitment of over $70 billion in U.S. capital and R&D spending.
• Full-year 2025 Non-GAAP EPS increased 17% to $8.98.

Negatives

• Significant decline in GARDASIL/GARDASIL 9 sales, down 39% to $5.2 billion for the full year, primarily due to lower demand in China and Japan.
• LAGEVRIO sales decreased 61% to $380 million for the full year.
• Marketing rights for Simponi and Remicade reverted to Johnson & Johnson, resulting in a 100% sales decline for these products for Merck.
• Fourth-quarter 2025 GAAP EPS decreased 20% to $1.19, primarily due to higher restructuring costs and amortization of intangible assets.
• Full-year 2025 GAAP gross margin declined to 74.8% from 76.3% in 2024, primarily due to higher restructuring costs, inventory write-offs, and amortization of intangible assets.
• Full-year 2025 Other (income) expense, net, was an expense of $151 million, compared to an income of $24 million in 2024, reflecting higher net interest expense and foreign exchange losses.
• The 2026 Non-GAAP EPS outlook of $5.00 to $5.15 is significantly lower than 2025's $8.98, primarily due to a one-time charge of approximately $3.65 per share for the Cidara acquisition.

Risks

• General industry conditions and competition.
• General economic factors, including interest rate and currency exchange rate fluctuations.
• Impact of pharmaceutical industry regulation and health care legislation in the United States and internationally.
• Global trends toward health care cost containment.
• Technological advances, new products, and patents attained by competitors.
• Challenges inherent in new product development, including obtaining regulatory approval.
• Ability to accurately predict future market conditions.
• Manufacturing difficulties or delays.
• Financial instability of international economies and sovereign risk.
• Dependence on the effectiveness of patents and other protections for innovative products.
• Exposure to litigation, including patent litigation, and/or regulatory actions.

Future Outlook

Merck anticipates full-year 2026 worldwide sales to be between $65.5 billion and $67.0 billion, including a positive foreign exchange impact of approximately 1%. The company expects full-year 2026 Non-GAAP EPS to range from $5.00 to $5.15, which reflects a significant one-time charge of approximately $3.65 per share for the acquisition of Cidara Therapeutics, along with an additional $0.30 per share in related financing and operational costs. The outlook does not assume any additional significant potential business development transactions.

Management Comments

• "In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving health outcomes for patients around the world."
• "Our business benefited from demand for our innovative portfolio, including for KEYTRUDA, increasing contributions from new launches in cardiometabolic and respiratory as well as vaccines, and strong performance of Animal Health."
• "The transformation of our portfolio, bolstered by the acquisitions of Verona Pharma and Cidara Therapeutics, is well underway, and momentum is building as we continue to execute on our strategy."
• "Our progress positions us to continue delivering on our purpose for patients and creating durable value for shareholders."

Industry Context

StockSavvy.ai notes that Merck's strong performance in oncology, particularly with KEYTRUDA, continues to solidify its leadership in a highly competitive therapeutic area. The successful launches of WINREVAIR and CAPVAXIVE demonstrate effective pipeline execution and diversification into cardiometabolic, respiratory, and vaccine markets, which are critical for long-term growth as patent expirations loom for established blockbusters. The significant decline in GARDASIL sales in key international markets highlights the challenges of market access and competition in the vaccine space, a common dynamic across the pharmaceutical industry. Strategic acquisitions like Cidara Therapeutics and Verona Pharma are consistent with broader industry trends of large pharmaceutical companies acquiring innovative smaller biotechs to replenish and expand their pipelines, especially in areas with high unmet medical need or novel mechanisms of action.

Comparison to Industry Standards

• Merck's 7% growth for KEYTRUDA in 2025 continues to outperform many oncology competitors, such as Bristol Myers Squibb's Opdivo, which has seen more modest growth or declines in recent periods, demonstrating KEYTRUDA's sustained market dominance and expansion into earlier-stage indications.
• The rapid uptake of WINREVAIR ($1.4 billion in its launch year) and CAPVAXIVE ($759 million) suggests a highly successful market entry, comparable to the initial launch trajectories of other successful new-to-market therapies in specialized areas, indicating strong clinical differentiation and commercial execution.
• The 39% decline in GARDASIL sales, particularly in China, contrasts with the overall growth in the global HPV vaccine market, where competitors like GlaxoSmithKline's Cervarix or emerging local players are vying for market share, indicating specific regional challenges for Merck.
• The acquisition of Cidara Therapeutics for $9.2 billion, adding MK-1406, is a substantial investment in line with major pharmaceutical M&A activities, such as Pfizer's acquisition of Seagen for $43 billion or AbbVie's acquisition of ImmunoGen for $10.1 billion, reflecting a strategic focus on pipeline expansion through external innovation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through pipeline growth and strategic acquisitions, but short-term EPS dilution from acquisition charges.
• Patients: Access to new transformative medicines and vaccines, including expanded access to key products at lower costs in the U.S.
• Employees: Continued investment in R&D and U.S. manufacturing could support job stability and growth.
• U.S. Government: Agreement to lower medicine costs and delay tariffs aligns with government objectives.

Next Steps

• Continued uptake of WINREVAIR in the U.S. and early launch uptake in international markets.
• Continued uptake of CAPVAXIVE in the U.S.
• FDA PDUFA dates in the second half of 2026 for KEYTRUDA/KEYTRUDA QLEX with Trodelvy for triple-negative breast cancer (TNBC).
• FDA PDUFA date of September 21, 2026, for WINREVAIR sBLA label update.
• Ongoing Phase 3 ANCHOR study for MK-1406 (from Cidara acquisition).
• Continued execution on the strategy of portfolio transformation, bolstered by acquisitions.
• Providing key products through a direct-to-patient program at affordable prices for eligible patients in the U.S.
• Making investments in the U.S. to reshore manufacturing, supported by a three-year delay on Section 232 tariffs.

Key Dates

Recommendation

Merck's core business shows robust growth, particularly in oncology and new product launches, indicating strong operational performance and pipeline execution. The strategic acquisitions are positive for long-term portfolio diversification. However, the significant one-time charge from the Cidara acquisition will substantially depress 2026 Non-GAAP EPS, creating near-term headwinds and uncertainty for investors. While the underlying business is strong, the immediate financial outlook suggests a 'hold' position until the impact of the acquisition is fully absorbed and the benefits of the expanded pipeline become clearer.

Keywords

Merck, MRK, Pharmaceuticals, Biotechnology, Oncology, KEYTRUDA, WINREVAIR, CAPVAXIVE, Animal Health, Vaccines, SEC Filing, Earnings Report, Financial Results, Pipeline, Acquisitions, Cidara Therapeutics, Verona Pharma, Drug Development, Healthcare, Biopharma